National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Patiromer (Veltassa®)

Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.

NCPE Assessment Process Complete
Rapid review received 11/10/2017
Rapid review completed 17/11/2017
Rapid Review outcome Full pharmacoeconomic assessment
recommended
Full pharmacoeconomic assessment commissioned by HSE 20/11/2017
Pre-submission consultation with Applicant 16/01/2018
Submission received from Applicant 13/04/2018
Preliminary review sent to Applicant 15/10/2018
NCPE assessment re-commenced 13/11/2018
Factual accuracy sent to Applicant 21/01/2019
NCPE assessment re-commenced 04/02/2019
NCPE assessment completed 13/02/2019
NCPE assessment outcome The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary

Re-submission of HTA

NCPE Assessment Process Ongoing
Re-submission of HTA commissioned by the HSE 30/06/2020
Pre-submission consultation with Applicant 23/11/2020
Current status Awaiting HTA submission from Applicant